Sandoz Says Amgen’s At-Risk Aflibercept Launch ‘Doesn’t Change Our Thinking’

FDA Approval For Sandoz’s Enzeevu Biosimilar Is In Hand, But Launch Date Unclear

 
• By Dave Wallace
  
Sandoz was asked about Amgen’s aflibercept launch during its Q3 call (Shutterstock)

More from Biosimilars

More from Generics Bulletin